Literature DB >> 27175030

Identification of a germline F692L drug resistance variant in cis with Flt3-internal tandem duplication in knock-in mice.

Oliver M Dovey1, Bin Chen2, Annalisa Mupo3, Mathias Friedrich3, Carolyn S Grove4, Jonathan L Cooper3, Benjamin Lee5, Ignacio Varela6, Yue Huang7, George S Vassiliou8.   

Abstract

Entities:  

Keywords:  acute myeloid leukemia; molecular pharmacology; tyrosine kinase inhibitor resistance

Mesh：

Substances：

Year:  2016        PMID： 27175030      PMCID： PMC4967582          DOI： 10.3324/haematol.2016.146159

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  17 in total

1.  Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.

Authors:  Elisabeth Zirm; Bärbel Spies-Weisshart; Florian Heidel; Ulf Schnetzke; Frank-Dietmar Böhmer; Andreas Hochhaus; Thomas Fischer; Sebastian Scholl
Journal:  Br J Haematol       Date:  2012-03-13       Impact factor: 6.998

2.  Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.

Authors:  Alan H Shih; Yanwen Jiang; Cem Meydan; Kaitlyn Shank; Suveg Pandey; Laura Barreyro; Ileana Antony-Debre; Agnes Viale; Nicholas Socci; Yongming Sun; Alexander Robertson; Magali Cavatore; Elisa de Stanchina; Todd Hricik; Franck Rapaport; Brittany Woods; Chen Wei; Megan Hatlen; Muhamed Baljevic; Stephen D Nimer; Martin Tallman; Elisabeth Paietta; Luisa Cimmino; Iannis Aifantis; Ulrich Steidl; Chris Mason; Ari Melnick; Ross L Levine
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

3.  Molecular and cellular effects of oncogene cooperation in a genetically accurate AML mouse model.

Authors:  K Reckzeh; O Bereshchenko; A Mead; M Rehn; S Kharazi; S-E Jacobsen; C Nerlov; J Cammenga
Journal:  Leukemia       Date:  2012-02-09       Impact factor: 11.528

4.  Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.

Authors:  Catherine C Smith; Chao Zhang; Kimberly C Lin; Elisabeth A Lasater; Ying Zhang; Evan Massi; Lauren E Damon; Matthew Pendleton; Ali Bashir; Robert Sebra; Alexander Perl; Andrew Kasarskis; Rafe Shellooe; Garson Tsang; Heidi Carias; Ben Powell; Elizabeth A Burton; Bernice Matusow; Jiazhong Zhang; Wayne Spevak; Prabha N Ibrahim; Mai H Le; Henry H Hsu; Gaston Habets; Brian L West; Gideon Bollag; Neil P Shah
Journal:  Cancer Discov       Date:  2015-04-06       Impact factor: 39.397

5.  Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias.

Authors:  Nicholas A Zorko; Kelsie M Bernot; Susan P Whitman; Ronald F Siebenaler; Elshafa H Ahmed; Gabriele G Marcucci; Daniel A Yanes; Kathleen K McConnell; Charlene Mao; Chidimma Kalu; Xiaoli Zhang; David Jarjoura; Adrienne M Dorrance; Nyla A Heerema; Benjamin H Lee; Gang Huang; Guido Marcucci; Michael A Caligiuri
Journal:  Blood       Date:  2012-06-06       Impact factor: 22.113

Review 6.  FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia.

Authors:  A Y H Leung; C-H Man; Y-L Kwong
Journal:  Leukemia       Date:  2012-07-16       Impact factor: 11.528

7.  Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing.

Authors:  Dirk Heckl; Monika S Kowalczyk; David Yudovich; Roger Belizaire; Rishi V Puram; Marie E McConkey; Anne Thielke; Jon C Aster; Aviv Regev; Benjamin L Ebert
Journal:  Nat Biotechnol       Date:  2014-06-22       Impact factor: 54.908

8.  FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.

Authors:  Benjamin H Lee; Zuzana Tothova; Ross L Levine; Kristina Anderson; Natalija Buza-Vidas; Dana E Cullen; Elizabeth P McDowell; Jennifer Adelsperger; Stefan Fröhling; Brian J P Huntly; Miloslav Beran; Sten Eirik Jacobsen; D Gary Gilliland
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

9.  A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice.

Authors:  A Mupo; L Celani; O Dovey; J L Cooper; C Grove; R Rad; P Sportoletti; B Falini; A Bradley; G S Vassiliou
Journal:  Leukemia       Date:  2013-03-12       Impact factor: 11.528

10.  FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors.

Authors:  Adam J Mead; Shabnam Kharazi; Deborah Atkinson; Iain Macaulay; Christian Pecquet; Stephen Loughran; Michael Lutteropp; Petter Woll; Onima Chowdhury; Sidinh Luc; Natalija Buza-Vidas; Helen Ferry; Sally-Ann Clark; Nicolas Goardon; Paresh Vyas; Stefan N Constantinescu; Ewa Sitnicka; Claus Nerlov; Sten Eirik W Jacobsen
Journal:  Cell Rep       Date:  2013-05-30       Impact factor: 9.423
View more
  2 in total

1.  Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.

Authors:  Oliver M Dovey; Jonathan L Cooper; Annalisa Mupo; Carolyn S Grove; Claire Lynn; Nathalie Conte; Robert M Andrews; Suruchi Pacharne; Konstantinos Tzelepis; M S Vijayabaskar; Paul Green; Roland Rad; Mark Arends; Penny Wright; Kosuke Yusa; Allan Bradley; Ignacio Varela; George S Vassiliou
Journal:  Blood       Date:  2017-08-23       Impact factor: 22.113

Review 2.  Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia.

Authors:  Francesca Musumeci; Chiara Greco; Giancarlo Grossi; Alessio Molinari; Silvia Schenone
Journal:  Cancers (Basel)       Date:  2018-11-09       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.